Profiltubi has been acquired by AUCTUS Capital Partners
The Alfieri family has sold Profiltubi S.p.A to AUCTUS Capital Partners AG.
Headquartered in Reggio Emilia, Italy, and founded over 40 years ago, Profiltubi is a significant player in the national and European steel market. It produces steel pipes
with high standards of quality and service. Profiltubi has 110 employees and 500 distributors in Italy, Germany, Switzerland, Austria, the Netherlands and France.
With over 250 company investments since 2001, AUCTUS is by far the most active German private equity firm. Its buy-and-build strategies have created more market leaders than any other fund in the country. As part of its succession solutions, strategy and corporate spin-offs, the firm takes a majority stake in medium-sized companies and/or provides capital for growth and acquisitions.
Oaklins’ team in Italy acted as the exclusive sell-side advisor in this transaction.
Talk to the deal team
Related deals
Sunlight Group has acquired a 51% stake in Lehmann Marine GmbH
Through its acquisition of a 51% stake in Lehmann Marine GmbH, Sunlight Group continues to strengthen its position in the growing energy solutions market, while expanding its portfolio of innovative technologies. With over 30 years of expertise in producing lead-acid and lithium-ion batteries, Sunlight Group has established itself as a leader in advanced battery technology.
Learn moreDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more